Dimensional Fund Advisors’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.1M Sell
540,053
-2,463
-0.5% -$79.6K ﹤0.01% 2016
2026
Q1
$17.7M Buy
542,516
+82,941
+18% +$2.67M ﹤0.01% 2030
2025
Q4
$16.2M Sell
459,575
-11,684
-2% -$414K ﹤0.01% 2084
2025
Q3
$12.4M Buy
471,259
+235,189
+100% +$7.02M ﹤0.01% 2222
2025
Q2
$6.26M Buy
+236,070
New +$6.21M ﹤0.01% 2453
2025
Q1
Sell
-100,762
Closed -$4.05M 3357
2024
Q4
$4.05M Sell
100,762
-10,394
-9% -$593K ﹤0.01% 2596
2024
Q3
$7.04M Buy
111,156
+64,266
+137% +$3.77M ﹤0.01% 2415
2024
Q2
$2.49M Sell
46,890
-262
-0.6% -$17.2K ﹤0.01% 2712
2024
Q1
$3.87M Sell
47,152
-14,981
-24% -$667K ﹤0.01% 2609
2023
Q4
$1.16M Sell
62,133
-364,631
-85% -$4.77M ﹤0.01% 2902
2023
Q3
$4.73M Sell
426,764
-107,568
-20% -$1.54M ﹤0.01% 2548
2023
Q2
$8.66M Hold
534,332
﹤0.01% 2321
2023
Q1
$8.9M Sell
534,332
-314,395
-37% -$3.25M ﹤0.01% 2281
2022
Q4
$7.98K Sell
848,727
-65,236
-7% -$291K ﹤0.01% 2296
2022
Q3
$2.49M Sell
913,963
-369,962
-29% -$1.21M ﹤0.01% 2647
2022
Q2
$3.71M Sell
1,283,925
-91,560
-7% -$227K ﹤0.01% 2540
2022
Q1
$4.13M Buy
1,375,485
+312,377
+29% +$1.12M ﹤0.01% 2595
2021
Q4
$4.89M Buy
1,063,108
+296,385
+39% +$1.66M ﹤0.01% 2572
2021
Q3
$4.82M Buy
766,723
+430,845
+128% +$2.66M ﹤0.01% 2600
2021
Q2
$2.01M Buy
335,878
+23,474
+8% +$139K ﹤0.01% 2866
2021
Q1
$1.98M Buy
312,404
+114,045
+57% +$802K ﹤0.01% 2860
2020
Q4
$1.12M Sell
198,359
-1,466
-0.7% -$8.88K ﹤0.01% 2957
2020
Q3
$1.16M Buy
199,825
+7,452
+4% +$51.3K ﹤0.01% 2897
2020
Q2
$1.39M Buy
192,373
+106,046
+123% +$704K ﹤0.01% 2854
2020
Q1
$404K Buy
86,327
+47,021
+120% +$289K ﹤0.01% 3093
2019
Q4
$315K Buy
+39,306
New +$287K ﹤0.01% 3201
2019
Q3
Sell
-212,048
Closed -$1.76M 3437
2019
Q2
$1.76M Hold
212,048
﹤0.01% 2931
2019
Q1
$2.11M Buy
212,048
+18,800
+10% +$157K ﹤0.01% 2883
2018
Q4
$1.48M Buy
+193,248
New +$2.31M ﹤0.01% 2936

Other funds holding VKTX

Dimensional Fund Advisors's VKTX Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Viking Therapeutics (VKTX) stake by 0.45% in Q2 2026, selling an estimated $79.6K and leaving 540,053 shares worth $21.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2016.

Dimensional Fund Advisors first reported a position in VKTX in Q4 2018 and has held it in 29 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Dimensional Fund Advisors held 540,053 shares of Viking Therapeutics worth $21.1M as of Q2 2026.
  • Dimensional Fund Advisors sold 2,463 Viking Therapeutics shares in Q2 2026, an estimated $79.6K.
  • Viking Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2016 holding.
  • Dimensional Fund Advisors first reported a position in Viking Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.